TB-500 Clinical Trial: The First Human Study (2026)

Everyone assumed the first human TB-500 trial would be about healing an injury. It’s about the heart — and that choice tells you a lot.

Abstract: The first registered TB-500 clinical trial in humans (NCT07487363) is a Phase 1/2 safety study in stable cardiovascular disease, not the musculoskeletal injury setting the peptide is marketed for. This guide explains exactly what the trial tests, why it targets the heart rather than a tendon, and why a registered safety study of a 7-amino-acid fragment can’t validate the full thymosin β4 protein behind most of the “TB-500” research.

The short version

If you searched “TB-500 clinical trial” before 2026, the honest answer was that there wasn’t one — not of the injected fragment people actually buy. The tissue-repair reputation of TB-500 rests on animal studies and on human trials of a different molecule (full-length thymosin β4, mostly as eye drops). In 2026 that gap finally narrowed: a registered, placebo-controlled Phase 1/2 study of the TB-500 fragment, NCT07487363, appeared on ClinicalTrials.gov.

The surprise is what it studies. It is not a hamstring, a tendon, or a torn rotator cuff. It enrolls adults with stable atherosclerotic cardiovascular disease (ASCVD) and measures safety plus cardiovascular biomarkers. The first time TB-500 is formally tested in people, the target organ is the heart. This article explains why that is less strange than it sounds, what the trial can and cannot prove, and how it fits alongside the parallel first BPC-157 human trial that landed the same year.

What the TB-500 clinical trial (NCT07487363) actually is

The registration describes a small, sequential, dose-escalation safety study — the standard shape of an early-phase first-in-human program, not a large efficacy trial.

Element	What the registration specifies
Identifier	NCT07487363
Drug	TB-500 — the thymosin β4 17–23 fragment — versus matching placebo
Phase	Phase 1/2 (safety and tolerability)
Population	Adults with documented stable ASCVD (e.g. prior MI >6 months ago, prior revascularization, stable angina with ischemia, or symptomatic peripheral artery disease)
Design	Three sequential dose cohorts; within each cohort, 3:1 randomization to TB-500 or placebo; participants, providers, investigators and assessors all masked
Duration	8 weeks of clinic-administered dosing, then a 4-week safety follow-up
Endpoints	Primary: safety and tolerability. Exploratory: vascular function and inflammation biomarkers

Two things are worth reading off that table. First, the primary endpoint is safety, not benefit — the trial is built to find out whether the fragment is tolerated and at what dose, not to prove it improves anything. Exploratory biomarkers are hypothesis-generating, not confirmatory. Second, the 3:1 randomization and dose-cohort structure are classic Phase 1/2: get a first read on a drug almost no one has taken under controlled conditions before.

As of this writing there are no posted results.

Why the first TB-500 trial is about the heart, not a hamstring

It looks odd that a peptide famous for muscle and tendon recovery debuts in a cardiology population. Mechanistically, it isn’t.

TB-500 is the actin-binding segment of thymosin β4, and that segment’s core job is the same wherever it acts: it sequesters G-actin, mobilizes cell migration, and supports angiogenesis — endothelial cells moving to line new blood vessels. Those are repair mechanisms in a wound, but they are also exactly the processes a damaged or ischemic heart needs. The strongest preclinical case for thymosin β4 was, in fact, cardiac: in a landmark 2004 Nature paper, Bock-Marquette and colleagues showed thymosin β4 promoted cardiomyocyte migration, survival, and functional cardiac repair after injury [preclinical / animal]. Small human cardiac signals followed — most notably a pilot in which thymosin β4–pretreated stem cells were associated with better heart function [early human, very small].

So a cardiovascular safety trial is a defensible place to start: there is a real mechanistic rationale, an established (and very high) human safety margin for thymosin β4 from earlier dosing studies, and biomarker endpoints that can be measured objectively over eight weeks. It also sidesteps the harder problem of proving accelerated tissue healing, which needs imaging endpoints and longer follow-up — the route the BPC-157 hamstring trial took instead.

The fragment problem: this trial won’t validate full-length TB4

Here is the distinction that most “TB-500” coverage blurs, and it changes how you should read this trial. TB-500 is not thymosin β4. Thymosin β4 (TB4) is the full 43-amino-acid protein. TB-500 is only its 7-amino-acid actin-binding fragment (LKKTETQ, residues 17–23). The fragment carries the actin/migration function but is missing the rest of the molecule — the first four residues linked to anti-inflammatory and anti-scar activity, the first fifteen linked to cell-survival/anti-apoptotic effects, plus antimicrobial and signaling regions.

That matters two ways here. NCT07487363 explicitly tests the 17–23 fragment, so a clean safety readout would be evidence about the fragment specifically — useful, because the fragment is what’s sold. But it also means the trial cannot retroactively validate the full-length-TB4 healing literature: a fragment result doesn’t transfer back to the whole protein any more than the whole protein’s results transferred down to the fragment. If you’ve ever assumed “TB-500 has human eye-healing data,” that data is on full-length TB4, not on what’s in the vial. We unpack this in depth in TB4 vs TB-500: why the full peptide beats the fragment.

The human evidence base — before this trial

Being precise about the prior record is what makes this milestone legible. Split by molecule:

• Full-length thymosin β4 (TB4), topical/ophthalmic — the strongest human data, but not the fragment. As RGN-259, TB4 eye drops reached Phase 3 in neurotrophic keratopathy (the SEER-1 trial reported fast, complete corneal healing versus placebo) [clinical — full-length TB4, topical] and showed meaningful dry-eye improvements in earlier controlled work, though it has not produced an FDA-approved product as of 2026.
• Full-length thymosin β4, systemic — early safety. A first-in-human, randomized, double-blind Phase 1 of recombinant human TB4 in healthy volunteers reported good tolerability [clinical — full-length TB4, safety only]. Older dosing work established a wide human safety margin for TB4.
• The TB-500 fragment itself — essentially nothing, until now. Independent 2026 evidence reviews agree there were no completed human efficacy trials of the injected TB-500 (17–23) fragment; its musculoskeletal reputation is built on animal models (faster muscle repair, stronger fracture healing) plus user anecdote. NCT07487363 is the first registered human study of the fragment.

In other words, the peptide most people inject is the one with the least human data — and this trial is the first attempt to change that.

What it can prove — and what it can’t

What a clean result could establish: that the TB-500 fragment, dosed over eight weeks in people with stable cardiovascular disease, is tolerated, with a defined dose range and a first look at its effect on vascular and inflammatory biomarkers.

What it can’t do, even if it goes well:

• It won’t show TB-500 heals injuries. This is a cardiovascular safety/biomarker study. It says nothing about tendons, muscle tears, or the recovery uses TB-500 is actually marketed for.
• It won’t validate full-length TB4. Different molecule. A fragment safety signal doesn’t confirm the TB4 healing literature.
• It won’t resolve the cancer-risk question. The same mechanisms that make β-thymosins interesting for repair — angiogenesis, cell migration / epithelial-mesenchymal transition, anti-apoptosis — are also the mechanisms by which a repair signal could, in theory, support an existing tumor. Eight weeks of biomarker data in a cardiac population doesn’t characterize that long-term risk, which is why anyone with a personal or family cancer history is routinely advised to avoid β-thymosins. See our peptide side-effects and safety guide for the full framing.
• It won’t make TB-500 an approved drug. Phase 1/2 is early, and “registered” is not “completed,” let alone “approved.”

2026: the year peptides entered human trials

NCT07487363 is best understood as half of a pair. The same year produced the first registered BPC-157 human RCT (NCT07437547, a double-blind, placebo-controlled Phase 2 in acute hamstring strain). Together they mark the moment the two flagship healing peptides moved from “animal data and anecdote” toward controlled human testing — BPC-157 going straight at a musculoskeletal efficacy endpoint, TB-500 entering through a cardiovascular safety door.

The shared lesson is about expectation-setting. A registered trial is a credibility step, not a verdict; neither has posted results; and both remain research/educational compounds, not approved drugs. If you’re studying these two together — the rationale for which we cover in the BPC-157 + TB-500 “Wolverine” stack guide — track the readouts, not the marketing.

What a serious researcher should take from this

Practically: nothing about this trial changes TB-500’s status today. It is sold for research/educational use only, it is not approved, and quality control falls on the buyer. The fragment-versus-full-length issue makes verification especially important — a vial labeled “TB-500” should be confirmed as the intended molecule, not full-length TB4 mislabeled (or vice versa), and for any injectable you want HPLC purity, mass-spec identity, plus endotoxin and sterility testing. Our walkthrough on how to read a peptide COA covers exactly what to demand, and how to read peptide studies and animal-to-human dose conversion explains why an animal dose isn’t a human dose. You can review the materials referenced here on the TB-500, BPC-157, and BPC-157 + TB-500 blend pages.

FAQ

Is there a human clinical trial for TB-500? Yes — as of 2026, NCT07487363 is the first registered human trial of the TB-500 (thymosin β4 17–23) fragment. It’s a Phase 1/2 safety study in adults with stable cardiovascular disease, with no posted results yet.

Why is the first TB-500 trial about cardiovascular disease and not injury healing? Because TB-500’s core mechanism — actin binding, cell migration, and angiogenesis — is directly relevant to cardiac and vascular repair, and the strongest preclinical thymosin β4 data was cardiac. A biomarker-based cardiovascular safety study is also faster and more measurable than a tissue-healing efficacy trial.

Does this trial prove TB-500 works for muscle or tendon recovery? No. It does not test musculoskeletal healing at all. TB-500’s injury-repair reputation still rests on animal studies and anecdote.

Is TB-500 the same as thymosin β4 (TB4)? No. TB-500 is a 7-amino-acid fragment of the full 43-amino-acid thymosin β4 protein. Most human thymosin β4 data (e.g. the RGN-259 eye-drop trials) used the full-length protein, not the fragment.

Is TB-500 FDA-approved? No. Neither the TB-500 fragment nor full-length thymosin β4 has an FDA-approved product as of 2026. TB-500 is sold for research/educational use only.

What’s the main safety concern with TB-500? The theoretical cancer-promotion risk: angiogenesis, cell migration/EMT, and anti-apoptosis are repair mechanisms that could, in principle, support an existing tumor. People with any cancer history are typically advised to avoid β-thymosins, and a short trial won’t resolve long-term safety.

References

1. ClinicalTrials.gov. TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD. Identifier NCT07487363 (registered 2026). https://clinicaltrials.gov/study/NCT07487363 — [clinical — registered Phase 1/2, no results]
2. ClinicalTrials.gov. BPC 157 for Acute Hamstring Muscle Strain Repair. Identifier NCT07437547 (registered 2026). https://clinicaltrials.gov/study/NCT07437547 — [clinical — registered RCT, no results]
3. Sosne G, et al. 0.1% RGN-259 (thymosin β4) ophthalmic solution in neurotrophic keratopathy: a randomized, placebo-controlled, double-masked Phase III trial (SEER-1). PMC9820614. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820614/ — [clinical — full-length TB4, topical]
4. Sosne G, et al. RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model. PMC6043477. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043477/ — [preclinical/clinical — full-length TB4, topical]
5. First-in-human, randomized, double-blind, single- and multiple-dose Phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. PMC8419156. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419156/ — [clinical — full-length TB4, safety]
6. Bock-Marquette I, et al. (2004). Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432(7016):466–472. PMID 15565145. https://pubmed.ncbi.nlm.nih.gov/15565145/ — [preclinical / animal]

---

Research and educational use only. This article describes what has been registered and reported in the scientific literature; it is not medical advice and not a recommendation to use TB-500. TB-500 and thymosin β4 are not approved by the FDA or any drug regulatory agency for human use. A registered clinical trial is not evidence of safety or efficacy. Consult a qualified healthcare professional before making any health decision. — Indexa Labs Research Team